Completed PHASE2 INTERVENTIONAL 1-arm NCT00814632

CC-10004 For The Treatment Of Vulvodynia

A Clinical Trial Of CC-10004 For The Treatment Of Vulvodynia

Sponsor: Celgene Corporation

Interventions CC-10004

Updated 8 times since 2017 Last updated: Aug 11, 2015 Started: Dec 31, 2008 Primary completion: Feb 28, 2011 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Vulvodynia and is currently completed. Celgene Corporation leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Jan 2026 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Kenneth Peters, MD

Data source: Corewell Health East

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Royal Oak, United States